C Difficile Infection

The area under the concentration-time curve (AUC) for vancomycin at discharge was the only modifiable factor found that was independently associated with patient safety outcomes.

Candace Cotto, RN, and Andrew Skinner, MD, discuss barriers to use of FMTs in managing CDI, highlighting clinician and patient education.

Experts comment on insurance coverage as a factor for the broader use of FMTs for the management of CDI.

The most frequent mutations found in the analyzed genomes was fluoroquinolone-associated mutations such as gyrA and there were 24 different sequence types were identified in the 130 isolates.

Kiwifruit supplementation did not have an impact on stool frequency or consistency, but magnesium oxide supplementation did result in improved stool frequency.

Candace Cotto, RN, reviews the process of incorporating fecal microbiota, live-jslm treatment into clinical practice, what patients can expect, and the room sanitation process after the procedure.

Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.

The median exposure of vedolizumab was 1.93 years and lower incidence rates were found for infliximab or adalimumab.

The interrupted time-series resulted in an increase in C. difficile infection incidences during the pre-pandemic period from 0.00 to 3.36 infections per 10,000 bed days during the COVID-19 pandemic.

RBX2660 showed similar efficacy and safety in treating patients with and without immunocompromised conditions.

Both the incidence and prevalence of inflammatory bowel disease is growing among the older population.

RBX2660 was the first ever live microbiota therapeutic to gain approval from the FDA for rCDI.

Joseph Reilly, BS, PharmD, BCGP, and Andrew Skinner, MD, discuss the potential benefits of using live-jslm early on to treat CDI, as well as the implications of this new treatment.

Joseph Reilly, BS, PharmD, BCGP, provides an overview of a new FDA-approved FMT therapy, live-jslm for the treatment of CDI.

Dr. Levine talks with Marketa Wills, MD, about the role of the payer in medicine.

For the maintenance trial, 42% and 55% of patients treated with upadacitinib 15 mg and 30 mg achieved clinical remission at week 52, compared to 14% of the placebo group.

Guselkumab is currently being evaluated as a treatment for both ulcerative colitis and Crohn's disease.

A redo surgery often improves the quality of life in a number of ways for patients with ulcerative colitis.

Pregnant women with celiac disease were not only at a higher risk of several pregnancy and delivery related complications, but also less likely to have a full-term uncomplicated delivery compared to the cohort without celiac disease.

In 2022, dupilumab became the first treatment approved by the US Food and Drug Administration for the treatment of patients with EoE.

The linaclotide group had significant improvements from baseline in the 12 week SBM frequency rate and 12-week stool consistency.

Candace Cotto, RN, and Andrew Skinner, MD, discuss the challenges of traditional fecal microbiota transplantation (FMT) in treatment of CDI.

Andrew Skinner, MD, reviews challenges in managing CDI, as well as the treatment guidelines from IDSA, SHEA, and ACG.

RBX2660 can be administered through a colonoscopy or rectally.

RBX2660 was originally approved by the FDA in 2022 and came to market in January 2023.

Joseph Reilly, BS, PharmD, BCGP; Candace Cotto, RN; and Andrew Skinner, MD, review C. difficile infection (CDI), its risk factors, symptoms, and quality of life for the patient.

Experts provide an overview of the gut microbiome and its importance to nutrition and overall health.

There were also 9 RT176 strains that carried the cfr(E)gene and one RT001 strain carried the cfr(C) gene. However, they were without a linezolid resistance.

The geometric mean duration of single-occupancy room isolation was 1.8 days in the mPOCT group, compared to 2.6 days in the control group.

RBX2660 and Vowst are now both approved for the prevention of recurrent C. difficile infections.